FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:815-821 March 28, 1996 Number 13 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background End-stage cirrhosis related to hepatitis C virus (HCV) is a common reason for liver transplantation, although viremia is known to persist in most cases. We investigated the impact of persistent HCV infection after liver transplantation on patient and graft survival and the effects of the HCV genotype and the degree of HLA matching between donor and recipient on the severity of recurrent hepatitis.

Methods A group of 149 patients with HCV infection who received liver transplants between January 1982 and April 1994 were followed for a median of 36 months; 623 patients without HCV infection who underwent liver transplantation for end-stage chronic liver disease were used as a control group. A total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens were obtained from 91 of the HCV-negative patients five years after transplantation.

Results Cumulative survival rates for the 149 patients with HCV infection were 79 percent after one year, 74 percent after three years, and 70 percent after five years, as compared with rates of 75 percent, 71 percent, and 69 percent, respectively, in the HCV-negative transplant recipients (P = 0.12). Of the 130 patients with hepatitis C infection who survived more than 6 months after transplantation, 15 (12 percent) had no evidence of chronic hepatitis on their most recent liver biopsy (median follow-up, 20 months), 70 (54 percent) had mild chronic hepatitis (median, 35 months), 35 (27 percent) had moderate chronic hepatitis (median, 35 months), and 10 (8 percent) had cirrhosis (median, 51 months). Graft loss occurred after a median of 303 days in 27 of the 149 patients, including 5 with HCV-related cirrhosis and 3 with HCV-related cholestatic hepatitis. Infection with HCV genotype 1b was associated with more severe graft injury, whereas the primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients had no significant effect on this variable.

Conclusions After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. After five years, the rates of graft and overall survival are similar between patients with and those without HCV infection.

Source Information

From the Institute of Liver Studies, King's College School of Medicine and Dentistry, London (E.J.G., B.C.P., N.V.N., H.M.S., J.A.U., P.T.D., R.W.), and Innogenetics, Ghent, Belgium (G.M.).

Address reprint requests to Dr. Williams at the Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom.

Full Text of this Article

Related Letters:

Long-Term Outcome of Hepatitis C Infection after Liver Transplantation
Pol S., Garrigue V., Legendre C., Heneghan M. A., Gane E. J., Naoumov N. V., Williams R.
Extract | Full Text  
N Engl J Med 1996; 335:522-523, Aug 15, 1996. Correspondence

This article has been cited by other articles:

• Riediger, C., Berberat, P. O., Sauer, P., Gotthardt, D., Weiss, K. H., Mehrabi, A., Merle, U., Stremmel, W., Encke, J. (2007). Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant 22: viii37-viii46 [Abstract] [Full Text]  
• Ramos-Casals, M, Font, J (2005). Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14: s64-s72 [Abstract]  
• Ramos-Casals, M., Font, J. (2005). Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14: s64-s72 [Abstract]  
• Sayegh, M. H., Carpenter, C. B. (2004). Transplantation 50 Years Later -- Progress, Challenges, and Promises. NEJM 351: 2761-2766 [Full Text]  
• Gruener, N. H., Jung, M.-C., Schirren, C. A. (2004). Recurrent hepatitis C virus infection after liver transplantation: natural course, therapeutic approach and possible mechanisms of viral control. J Antimicrob Chemother 54: 17-20 [Abstract] [Full Text]  
• Andreoni, K. A., Lin, J. I., Groben, P. A. (2004). Liver Transplantation 27 Years after Bone Marrow Transplantation from the Same Living Donor. NEJM 350: 2624-2625 [Full Text]  
• Peffault de Latour, R., Levy, V., Asselah, T., Marcellin, P., Scieux, C., Ades, L., Traineau, R., Devergie, A., Ribaud, P., Esperou, H., Gluckman, E., Valla, D., Socie, G. (2004). Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103: 1618-1624 [Abstract] [Full Text]  
• Krahn, M., Wong, J. B., Heathcote, J., Scully, L., Seeff, L. (2004). Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990. Med Decis Making 24: 20-29 [Abstract]  
• Mohsen, A H, Easterbrook, P J, Taylor, C, Portmann, B, Kulasegaram, R, Murad, S, Wiselka, M, Norris, S (2003). Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 52: 1035-1040 [Abstract] [Full Text]  
• Bizollon, T, Ahmed, S N S, Radenne, S, Chevallier, M, Chevallier, P, Parvaz, P, Guichard, S, Ducerf, C, Baulieux, J, Zoulim, F, Trepo, C (2003). Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 52: 283-287 [Abstract] [Full Text]  
• Wali, M, Harrison, R F, Gow, P J, Mutimer, D (2002). Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51: 248-252 [Abstract] [Full Text]  
• Shaw, A S, Ryan, S M, Beese, R C, Norris, S, Bowles, M, Rela, M, Sidhu, P S (2002). Liver transplantation. Imaging 14: 314-328 [Abstract] [Full Text]  
• Guido, M, Fagiuoli, S, Tessari, G, Burra, P, Leandro, G, Boccagni, P, Cillo, U, Naccarato, R, Rugge, M (2002). Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 50: 697-700 [Abstract] [Full Text]  
• Prince, M I, Hudson, M (2002). Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages. Postgrad. Med. J. 78: 135-141 [Abstract] [Full Text]  
• Li, C., Candotti, D., Allain, J.-P. (2001). Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1. J. Virol. 75: 12412-12420 [Abstract] [Full Text]  
• Walsh, K, Alexander, G J M (2001). Update on chronic viral hepatitis. Postgrad. Med. J. 77: 498-505 [Abstract] [Full Text]  
• Bizollon, T, Ahmed, S N S., Guichard, S, Chevallier, P, Adham, M, Ducerf, C, Baulieux, J, Trepo, C (2000). Anti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients. Gut 47: 698-702 [Abstract] [Full Text]  
• ZEKRI, A.-R. N., BAHNASSY, A. A., SHAARAWY, S. M., MANSOUR, O. A., MADUAR, M. A., KHALED, H. M., EL-AHMADI, O. (2000). Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma. J Med Microbiol 49: 89-95 [Abstract] [Full Text]  
• Devlin, J, O'Grady, J (1999). Indications for referral and assessment in adultliver transplantation: a clinical guideline. Gut 45: VI1-22 [Full Text]  
• MUTIMER, D (1999). Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection?. Gut 45: 475-476 [Full Text]  
• Papatheodoridis, G V, Barton, S G R G, Andrew, D, Clewley, G, Davies, S, Dhillon, A P, Dusheiko, G, Davidson, B, Rolles, K, Burroughs, A K (1999). Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 45: 427-434 [Abstract] [Full Text]  
• Casino, C., Lilli, D., Rivanera, D., Comanducci, A., Rossi, M., Casciaro, G., Pecorella, I., Alfani, D., Mancini, C. (1999). Diagnostic Value of Anti-Hepatitis C Virus (HCV) Core Immunoglobulin M in Recurrence of HCV Infection after Orthotopic Liver Transplantation. J. Clin. Microbiol. 37: 2726-2728 [Abstract] [Full Text]  
• BERENGUER, M, WRIGHT, T L (1999). Hepatitis C and liver transplantation. Gut 45: 159-163 [Full Text]  
• BIZOLLON, T, DUCERF, C, TREPO, C, MUTIMER, D (1999). Hepatitis C virus recurrence after liver transplantation. Gut 44: 575-578 [Abstract] [Full Text]  
• Khettry, U., Robiou, C., Jenkins, R. L., Loda, M., Lewis, W. D. (1998). Recurrent Hepatitis C in Liver Allografts: Early Histologic Indicators. INT J SURG PATHOL 6: 197-204 [Abstract]  
• PEREIRA, S P, WILLIAMS, R (1998). Limits to liver transplantation in the UK. Gut 42: 883-885 [Full Text]  
• Lerat, H., Rumin, S., Habersetzer, F., Berby, F., Trabaud, M.-A., Trepo, C., Inchauspe, G. (1998). In Vivo Tropism of Hepatitis C Virus Genomic Sequences in Hematopoietic Cells: Influence of Viral Load, Viral Genotype, and Cell Phenotype. Blood 91: 3841-3849 [Abstract] [Full Text]  
• Gordon, F H, Mistry, P K, Sabin, C A, Lee, C A (1998). Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 42: 744-749 [Abstract] [Full Text]  
• Nagata, I., Tzampouras, N., Chokshi, S., Naoumov, N. V, Cheeseman, P., Smith, H. M, Baker, A. J, Williams, R., Mieli-Vergani, G. (1997). Hepatitis GB virus-C/hepatitis G virus infection in liver disease. Arch. Dis. Child. 77: 223-226 [Abstract] [Full Text]  
• Pol, S., Garrigue, V., Legendre, C., Heneghan, M. A., Gane, E. J., Naoumov, N. V., Williams, R. (1996). Long-Term Outcome of Hepatitis C Infection after Liver Transplantation. NEJM 335: 522-523 [Full Text]